Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
4(100.0%)
4Total
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03480971Phase 2Recruiting

Treatment of Radiation and Cisplatin Induced Toxicities with Tempol

Role: lead

NCT05491928Unknown

Treatment of Metastatic Cancer in Terminally Diagnosed Patients

Role: lead

NCT04887311Phase 2Unknown

MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia

Role: lead

NCT04876755Phase 2Unknown

MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer

Role: lead

NCT04337099Unknown

A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer

Role: lead

NCT04874506Phase 2Unknown

MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)

Role: lead

All 6 trials loaded